MeSH D008659 - metabolic diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009750:Nutritional and metabolic diseases
D000137:Acid-base imbalance
0 Companies
0 Drugs
Success rate
D001851:Metabolic bone diseases
0 Companies
0 Drugs
Success rate
D001928:Metabolic brain diseases
0 Companies
0 Drugs
Success rate
D008661:Inborn errors metabolism
D010760:Phosphorus metabolism disorders
0 Companies
0 Drugs
Success rate
D011164:Porphyrias
0 Companies
0 Drugs
Success rate
D012875:Metabolic skin diseases
0 Companies
0 Drugs
Success rate
D019189:Iron metabolism disorders
0 Companies
0 Drugs
Success rate
D019282:Wasting syndrome
0 Companies
0 Drugs
Success rate
D024821:Metabolic syndrome
0 Companies
0 Drugs
Success rate
D028361:Mitochondrial diseases
0 Companies
0 Drugs
Success rate
D049914:Dna repair-deficiency disorders
0 Companies
0 Drugs
Success rate
D052439:Lipid metabolism disorders
0 Companies
0 Drugs
Success rate
D057165:Proteostasis deficiencies
0 Companies
0 Drugs
Success rate
D065906:Hyperlactatemia
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AstraZeneca | Dapagliflozin, Saxagliptin | Qtern | 2016-07-15 | $5 M | Y2017 |
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
0%0/2
Phase 3
100%2/2
Approved: 2Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use